Selective dorsal rhizotomy; evidence on cost-effectiveness from England

被引:3
|
作者
Pennington, Mark [1 ,2 ]
Summers, Jennifer [2 ,3 ]
Coker, Bola [2 ,3 ]
Eddy, Saskia [2 ,3 ]
Kartha, Muralikrishnan R. [1 ,2 ]
Edwards, Karen [4 ]
Freeman, Robert [4 ]
Goodden, John [5 ]
Powel, Helen [6 ]
Verity, Christopher [7 ]
Peacock, Janet L. [2 ,3 ]
机构
[1] Kings Coll London, Inst Psychiat Psychol & Neurosci, Kings Hlth Econ, London, England
[2] Kings Coll London, Kings Technol Evaluat Ctr, Sch Biomed Engn & Imaging Sci, London, England
[3] Kings Coll London, Sch Populat Hlth & Environm Sci, London, England
[4] Robert Jones & Agnes Hunt Hosp, Oswestry, Shrops, England
[5] Leeds Gen Infirm, Dept Neurosurg, Leeds, W Yorkshire, England
[6] Natl Inst Hlth & Care Excellence, Manchester, Lancs, England
[7] Addenbrookes Hosp, Cambridge, England
来源
PLOS ONE | 2020年 / 15卷 / 08期
关键词
CONTINUOUS INTRATHECAL BACLOFEN; SPASTIC CEREBRAL-PALSY; GROSS MOTOR FUNCTION; TOXIN TYPE-A; BOTULINUM TOXIN; POSTERIOR RHIZOTOMY; FUNCTIONAL BENEFITS; CHILDREN; MANAGEMENT; STABILITY;
D O I
10.1371/journal.pone.0236783
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Objectives Selective dorsal rhizotomy (SDR) has gained interest as an intervention to reduce spasticity and pain, and improve quality of life and mobility in children with cerebral palsy mainly affecting the legs (diplegia). We evaluated the cost-effectiveness of SDR in England. Methods Cost-effectiveness was quantified with respect to Gross Motor Function Measure (GMFM-66) and the pain dimension of the Cerebral Palsy Quality of Life questionnaire for Children (CPQOL-Child). Data on outcomes following SDR over two years were drawn from a national evaluation in England which included 137 children, mean age 6.6 years at surgery. The incremental impact of SDR on GMFM-66 was determined through comparison with data from a historic Canadian cohort not undergoing SDR. Another single centre provided data on hospital care over ten years for 15 children undergoing SDR at a mean age of 7.0 years, and a comparable cohort managed without SDR. The incremental impact of SDR on pain was determined using a before and after comparison using data from the national evaluation. Missing data were imputed using multiple imputation. Incremental costs of SDR were determined as the difference in costs over 5 years for the patients undergoing SDR and those managed without SDR. Uncertainty was quantified using bootstrapping and reported as the cost-effectiveness acceptability curve. Results In the base case, the incremental cost-effectiveness ratios (ICERs) for SDR are 1,382 pound and 903 pound with respect to a unit improvement in GMFM-66 and the pain dimension of CPQOL-Child, respectively. Inclusion of data to 10 years indicates SDR is cheaper than management without SDR. Incremental costs and ICERs for SDR rose in sensitivity analysis applying an alternative regression model to cost data. Conclusions Data on outcomes from a large observational study of SDR and long-term cost data on children who did and did not receive SDR indicates SDR is cost-effective.
引用
收藏
页数:13
相关论文
共 50 条
  • [41] Cost-effectiveness analysis and formulary decision making in England: Findings from research
    Williams, Iestyn P.
    Bryan, Stirling
    SOCIAL SCIENCE & MEDICINE, 2007, 65 (10) : 2116 - 2129
  • [42] Cost, Effectiveness, and Cost-Effectiveness
    Diamond, George A.
    Kaul, Sanjay
    CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2009, 2 (01): : 49 - 54
  • [43] From efficacy to cost-effectiveness
    Kernick, DP
    LANCET, 1997, 350 (9093): : 1781 - 1781
  • [44] EFFECTIVENESS AND COST-EFFECTIVENESS OF SCREENING FOR FAMILIAL HYPERCHOLESTEROLEMIA - A REVIEW OF EVIDENCE FROM MODELING STUDIES
    Jahn, Beate
    Santamaria, Julia
    Dieplinger, Hans
    Binder, Christoph
    Ebenbichler, Christoph
    Scholl-Buergi, Sabine
    Annette, Conrads-Frank
    Rochau, Ursula
    Kuehne, Felicitas
    Stojkov, Igor
    Todorovic, Jovan
    Siebert, Uwe
    MEDICAL DECISION MAKING, 2021, 41 (04) : E322 - E323
  • [45] Cost and cost-effectiveness of PPM-DOTS for tuberculosis control: evidence from India
    Floyd, Katherine
    Arora, V. K.
    Murthy, K. J. R.
    Lonnroth, Knut
    Singla, Neeta
    Akbar, Y.
    Zignol, Matteo
    Uplekar, Mukund
    BULLETIN OF THE WORLD HEALTH ORGANIZATION, 2006, 84 (06) : 437 - 445
  • [46] Conservation cost-effectiveness: a review of the evidence base
    Pienkowski, Thomas
    Cook, Carly
    Verma, Megha
    Carrasco, Luis Roman
    CONSERVATION SCIENCE AND PRACTICE, 2021, 3 (05)
  • [47] Cost-effectiveness findings not based on available evidence
    Fenn, CG
    MEDICAL JOURNAL OF AUSTRALIA, 2004, 181 (06) : 339 - +
  • [48] Cost-Effectiveness of CCTV Surveillance Systems: Evidence from a Polish City
    Matczak, Piotr
    Wojtowicz, Andrzej
    Dabrowski, Adam
    Maczka, Krzysztof
    EUROPEAN JOURNAL ON CRIMINAL POLICY AND RESEARCH, 2023, 29 (04) : 555 - 577
  • [49] The cost-effectiveness of the English smoking treatment services: evidence from practice
    Godfrey, C
    Parrott, S
    Coleman, T
    Pound, E
    ADDICTION, 2005, 100 : 70 - 83
  • [50] Cost-effectiveness of screening for retinopathy of prematurity (ROP): Evidence from Canada
    Lee, SK
    Normand, C
    McMillan, DD
    Lee, D
    Ohlsson, A
    PEDIATRIC RESEARCH, 1999, 45 (04) : 248A - 248A